#SFHS2608352AOrder of April 8, 2026, Amending the List of Pharmaceutical Specialties Approved for Use by Communities and Various Public Services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The law expands the use of certain pharmaceutical specialties for preventing acute organ rejection in pediatric patients who have undergone various transplants. It specifically includes the combination of mycophenolate mofetil with cyclosporine and corticosteroids for children who received kidney, heart, or liver transplants. This affects healthcare providers and pharmacists within the public health service who need to adjust their inventory and care plans for these patients.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Expanded the indications for certain pharmaceutical products
- Includes specific drugs for pediatric transplant patients
- Impacts healthcare providers and pharmacists
Obligations
What this law requires
Update the official list of pharmaceutical specialties approved for use by public communities and services to include the three CELLCEPT formulations (CIP codes: 34009 359 529 3 6, 34009 359 525 8 5, 34009 359 527 0 7) for the newly approved pediatric transplant indications
Authorize use of mycophenolate mofetil (CELLCEPT) in combination with cyclosporine and corticosteroids for pediatric patients aged 1-2 years who have received kidney transplants within public healthcare services
Authorize use of mycophenolate mofetil (CELLCEPT) in combination with cyclosporine and corticosteroids for pediatric patients aged 1-18 years who have received heart or liver transplants within public healthcare services
Adjust pharmaceutical inventory and procurement protocols in public healthcare services to ensure availability of CELLCEPT 1 g/5 ml suspension, 250 mg capsules, and 500 mg tablets for pediatric transplant patients
Update patient care protocols and treatment plans in public healthcare services to incorporate mycophenolate mofetil as an approved immunosuppressant for the specified pediatric transplant populations